Tela Bio Stock Today
| TELA Stock | USD 5.71 0.21 3.82% |
Performance0 of 100
| Odds Of DistressOver 81
|
Tela Bio is trading at 5.71 as of the 5th of June 2024, a 3.82% increase since the beginning of the trading day. The stock's open price was 5.5. Tela Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Tela Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of June 2022 and ending today, the 5th of June 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 8th of November 2019 | Category Healthcare | Classification Health Care |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients anatomy. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. The company has 24.66 M outstanding shares of which 1.15 M shares are at this time shorted by private and institutional investors with about 5.0 trading days to cover. More on Tela Bio
Moving together with Tela Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tela Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tela Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tela Bio's financial leverage. It provides some insight into what part of Tela Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tela Bio (TELA) is traded on NASDAQ Exchange in USA. It is located in 1 Great Valley Parkway, Malvern, PA, United States, 19355 and employs 227 people. Tela Bio is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 135.6 M. Tela Bio conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 24.66 M outstanding shares of which 1.15 M shares are at this time shorted by private and institutional investors with about 5.0 trading days to cover.
Tela Bio currently holds about 27.73 M in cash with (40.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.9.
Check Tela Bio Probability Of Bankruptcy
Ownership AllocationThe majority of Tela Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tela Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tela Bio. Please pay attention to any change in the institutional holdings of Tela Bio as this could imply that something significant has changed or is about to change at the company.
Check Tela Ownership Details
Tela Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Paradigm Capital Management, Inc. | 2024-03-31 | 515.3 K | |
| Kennedy Capital Management Inc | 2024-03-31 | 383.1 K | |
| State Street Corporation | 2024-03-31 | 375.4 K | |
| Geode Capital Management, Llc | 2024-03-31 | 349.7 K | |
| Worth Venture Partners, Llc | 2023-12-31 | 345.3 K | |
| Pentwater Capital Management Lp | 2024-03-31 | 308.6 K | |
| Perkins Capital Management Inc | 2024-03-31 | 210 K | |
| Meros Investment Management, Lp | 2024-03-31 | 150.3 K | |
| Northern Trust Corp | 2024-03-31 | 133 K | |
| Essex Woodlands Health Ventures | 2024-03-31 | 4.1 M | |
| Orbimed Advisors, Llc | 2024-03-31 | 2.8 M |
Tela Bio Historical Income Statement
Tela Stock Against Markets
Tela Bio Corporate Management
| Megan Smeykal | Corporate VP | Profile | |
| Taylor Ocasio | General Secretary | Profile | |
| Antony Koblish | President, Cofounder | Profile | |
| Louisa Smith | Investor Officer | Profile | |
| Skott Greenhalgh | Chief Officer | Profile | |
| Peter Murphy | Chief Officer | Profile | |
| Roberto JD | CFO COO | Profile |
Additional Information and Resources on Investing in Tela Stock
When determining whether Tela Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tela Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tela Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tela Bio Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tela Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tela Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 2.608 | Quarterly Revenue Growth 0.394 | Return On Assets (0.43) | Return On Equity (4.60) |
The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tela Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tela Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.